Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 194

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 194
---
all aspects of our business operations. The widespread use of technology, including mobile devices, cloud computing, and the internet,
gives rise to cybersecurity risks, including security breach, espionage, system disruption, theft and inadvertent release of information.
Our business involves the storage and transmission of numerous classes of sensitive and/or confidential information and intellectual property,
including information relating to suppliers, private information about employees, and financial and strategic information about us and
our business partners. If we fail to effectively assess and identify cybersecurity risks associated with the use of technology in our
business operations, we may become increasingly vulnerable to such risks. Additionally, while we have implemented measures to prevent
security breaches and cyber incidents, our preventative measures and incident response efforts may not be entirely effective. The theft,
destruction, loss, misappropriation, or release of sensitive and/or confidential information or intellectual property, or interference
with our information technology systems or the technology systems of third parties on which we rely, could result in business disruption,
negative publicity, brand damage, violation of privacy laws, loss of customers, potential liability and competitive disadvantage.

Use of social media platforms presents
new risks.

We believe that our potential
patient population is active on social media. Social media practices in the pharmaceutical and biotechnology industries are evolving,
which creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social
media platforms to comment on the effectiveness of, or adverse experiences with, a product candidate, which could result in reporting
obligations. In addition, there is a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments
about us or our product candidates on any social networking website. In addition, our employees or third parties with whom we contract,
such as our CROs or CMOs, may knowingly or inadvertently make use of social media in a manner that may give rise to liability, lead to
the loss of trade secrets or other intellectual property or result in public exposure of personal information of our employees, clinical
trial patients, customers and others or information regarding our product candidates or clinical trials. Any of these events could have
a material adverse effect on our business, prospects, operating results and financial condition and could adversely affect the price of
our common shares.

Risks Related to our Intellectual Property

We depend on obtaining certain patents and
protecting our proprietary rights.

Our success will depend, in
part, on our ability to obtain patents, maintain trade secret protection and operate without infringing on